Relative Range

Updated daily · as of Jul 17, 2026

XLV

State Street Health Care Select Sector SPDR ETF

#6 of 11 in US Sectors by own-history percentile (high → low)

Near lows (6%)

Relative to SPY

Relative price history

XLV ÷ SPY, 10-year range, as of Jul 17, 2026

Position in 10-year rangeNear lows (6%)ranked vs 2,513 trading days
12m vs S&P 500-0.0%Change in relative price over ~12 months
Category rank#6of 11 in US Sectors
~1 week change+3.6 ptsvs Jun 30, 2026 reading (2.4%)
~1 month change+5.7 ptsvs May 29, 2026 reading (0.3%)
Trailing PE29.0xas of Jul 17, 2026
Current ratio0.2167
AUM$40.6BFund assets under management
Avg volume10.5MApprox. 3-month daily shares

How the reading moved

These changes re-score an older XLV÷SPY ratio against today's 10-year window, so they show whether the relative price has drifted toward the highs or lows of its own history — not a peer ranking and not a return forecast.

  • About one week: +3.6 pts (from 2.4% on Jun 30, 2026 to 6% now)
  • About one month: +5.7 pts (from 0.3% on May 29, 2026 to 6% now)

US Sectors

Where this sits among peers

US Sectors · XLV highlighted · same axes as the category chart on the home page

Top holdings

LLYEli Lilly and Co16.5%
JNJJohnson & Johnson10.6%
ABBVAbbVie Inc7.7%
UNHUnitedHealth Group Inc6.6%
MRKMerck & Co Inc5.5%
AMGNAmgen Inc3.4%
TMOThermo Fisher Scientific Inc3.2%
ABTAbbott Laboratories2.8%
GILDGilead Sciences Inc2.7%
ISRGIntuitive Surgical Inc2.5%

Holdings snapshot as of Jul 17, 2026.

What moves this

XLV's earnings are relatively steady, but the sector's price relative to the market has periodically been pushed down by policy overhang — drug-pricing legislation, patent-cliff fears, or election-year rhetoric — that can persist independently of how the underlying businesses are actually performing.

FAQ

Why would a low-percentile reading not simply mean healthcare is 'due' for a rebound?

A sustained discount can reflect a real, ongoing risk (such as pending legislation) rather than a temporary mispricing — this site reports where the price sits, not why it will or won't revert.

Does this page account for individual drug approvals or trial results?

No — the sector-level ratio smooths over single-company news; a specific stock catalyst may not move the whole sector's relative price at all.

Is healthcare's relative price mainly driven by rates like utilities are?

Less so — healthcare's swings are more often tied to regulatory and litigation headlines than to the interest-rate cycle.

US Sectors

Related in this category